| Dr James Anthony Lucio, MD | |
|
1121 N Central Ave, Suite B, Kissimmee, FL 34741-4405 | |
| (407) 933-1221 | |
| (407) 933-0747 |
| Full Name | Dr James Anthony Lucio |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 37 Years |
| Location | 1121 N Central Ave, Kissimmee, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649235151 | NPI | - | NPPES |
| 12472 | Other | FL | BLUE CROSS BLUE SHIELD |
| 372186800 | Medicaid | FL | |
| 103380 | Other | FL | AVMED PROVIDER ID |
| 4323220 | Other | FL | AETNA PROVIDER ID |
| 4800797 | Other | FM | UHC PROVIDER ID |
| 3816548001 | Other | FL | CIGNA PROVIDER ID |
| Facility Name | Location | Facility Type |
|---|---|---|
| Adventhealth Orlando | Orlando, FL | Hospital |
| Adventhealth Lake Wales | Lake wales, FL | Hospital |
| Adventhealth Heart Of Florida | Davenport, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Florida Hospital Medical Group Inc | 0749186153 | 1163 |
News Archive
Microbix Biosystems Inc., a biotechnology company commercializing novel technologies for influenza vaccine manufacturing and livestock semen sexing, in addition to a core business of virology products, today reported financial results for the first quarter of fiscal 2011. For the quarter ended December 31, 2010, Microbix reported revenues of $812,694, a 34% decrease from $1,226,538 for the same period in 2009.
Javelin Pharmaceuticals, Inc. announced today that it had received a binding offer from Hospira, Inc. and its wholly-owned subsidiary, Discus Acquisition Corporation ("Discus"), to enter into a merger agreement, a loan and security agreement and intellectual property security agreements whereby Discus will, subject to certain conditions, commence an all cash tender offer to acquire all of the outstanding shares of Javelin at a per share price of $2.20.
The University of Texas at Arlington has successfully patented in Europe an implantable medical device that attracts and kills circulating cancer cells that was invented by a faculty member. This cancer trap can be used for early diagnosis and treatment of metastasized cancer.
On the heels of the 2014 hurricane season, researchers are calling for home parenteral and enteral nutrition (HPEN) consumers and their homecare providers to have a comprehensive emergency preparedness plan (EPP) to ensure that special needs are met during the time of a disaster.
Sinai Hospital of Baltimore endocrinologist, Henry G. Fein, M.D., today presented new research showing that patients with Cushing's syndrome, a rare disease that can lead to extreme weight gain, type 2 diabetes, high blood pressure and psychological issues, experienced significant, sustained weight loss while taking oral medication daily over a number of years to manage symptoms of the disease.
› Verified 3 days ago
| Entity Name | Florida Hospital Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225034234 PECOS PAC ID: 0749186153 Enrollment ID: O20031208000807 |
News Archive
Microbix Biosystems Inc., a biotechnology company commercializing novel technologies for influenza vaccine manufacturing and livestock semen sexing, in addition to a core business of virology products, today reported financial results for the first quarter of fiscal 2011. For the quarter ended December 31, 2010, Microbix reported revenues of $812,694, a 34% decrease from $1,226,538 for the same period in 2009.
Javelin Pharmaceuticals, Inc. announced today that it had received a binding offer from Hospira, Inc. and its wholly-owned subsidiary, Discus Acquisition Corporation ("Discus"), to enter into a merger agreement, a loan and security agreement and intellectual property security agreements whereby Discus will, subject to certain conditions, commence an all cash tender offer to acquire all of the outstanding shares of Javelin at a per share price of $2.20.
The University of Texas at Arlington has successfully patented in Europe an implantable medical device that attracts and kills circulating cancer cells that was invented by a faculty member. This cancer trap can be used for early diagnosis and treatment of metastasized cancer.
On the heels of the 2014 hurricane season, researchers are calling for home parenteral and enteral nutrition (HPEN) consumers and their homecare providers to have a comprehensive emergency preparedness plan (EPP) to ensure that special needs are met during the time of a disaster.
Sinai Hospital of Baltimore endocrinologist, Henry G. Fein, M.D., today presented new research showing that patients with Cushing's syndrome, a rare disease that can lead to extreme weight gain, type 2 diabetes, high blood pressure and psychological issues, experienced significant, sustained weight loss while taking oral medication daily over a number of years to manage symptoms of the disease.
› Verified 3 days ago
| Entity Name | Pulmonary Disease Specialists, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649484809 PECOS PAC ID: 4789648072 Enrollment ID: O20041116001061 |
News Archive
Microbix Biosystems Inc., a biotechnology company commercializing novel technologies for influenza vaccine manufacturing and livestock semen sexing, in addition to a core business of virology products, today reported financial results for the first quarter of fiscal 2011. For the quarter ended December 31, 2010, Microbix reported revenues of $812,694, a 34% decrease from $1,226,538 for the same period in 2009.
Javelin Pharmaceuticals, Inc. announced today that it had received a binding offer from Hospira, Inc. and its wholly-owned subsidiary, Discus Acquisition Corporation ("Discus"), to enter into a merger agreement, a loan and security agreement and intellectual property security agreements whereby Discus will, subject to certain conditions, commence an all cash tender offer to acquire all of the outstanding shares of Javelin at a per share price of $2.20.
The University of Texas at Arlington has successfully patented in Europe an implantable medical device that attracts and kills circulating cancer cells that was invented by a faculty member. This cancer trap can be used for early diagnosis and treatment of metastasized cancer.
On the heels of the 2014 hurricane season, researchers are calling for home parenteral and enteral nutrition (HPEN) consumers and their homecare providers to have a comprehensive emergency preparedness plan (EPP) to ensure that special needs are met during the time of a disaster.
Sinai Hospital of Baltimore endocrinologist, Henry G. Fein, M.D., today presented new research showing that patients with Cushing's syndrome, a rare disease that can lead to extreme weight gain, type 2 diabetes, high blood pressure and psychological issues, experienced significant, sustained weight loss while taking oral medication daily over a number of years to manage symptoms of the disease.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr James Anthony Lucio, MD 1121 N Central Ave, Suite B, Kissimmee, FL 34741-4405 Ph: (407) 933-1221 | Dr James Anthony Lucio, MD 1121 N Central Ave, Suite B, Kissimmee, FL 34741-4405 Ph: (407) 933-1221 |
News Archive
Microbix Biosystems Inc., a biotechnology company commercializing novel technologies for influenza vaccine manufacturing and livestock semen sexing, in addition to a core business of virology products, today reported financial results for the first quarter of fiscal 2011. For the quarter ended December 31, 2010, Microbix reported revenues of $812,694, a 34% decrease from $1,226,538 for the same period in 2009.
Javelin Pharmaceuticals, Inc. announced today that it had received a binding offer from Hospira, Inc. and its wholly-owned subsidiary, Discus Acquisition Corporation ("Discus"), to enter into a merger agreement, a loan and security agreement and intellectual property security agreements whereby Discus will, subject to certain conditions, commence an all cash tender offer to acquire all of the outstanding shares of Javelin at a per share price of $2.20.
The University of Texas at Arlington has successfully patented in Europe an implantable medical device that attracts and kills circulating cancer cells that was invented by a faculty member. This cancer trap can be used for early diagnosis and treatment of metastasized cancer.
On the heels of the 2014 hurricane season, researchers are calling for home parenteral and enteral nutrition (HPEN) consumers and their homecare providers to have a comprehensive emergency preparedness plan (EPP) to ensure that special needs are met during the time of a disaster.
Sinai Hospital of Baltimore endocrinologist, Henry G. Fein, M.D., today presented new research showing that patients with Cushing's syndrome, a rare disease that can lead to extreme weight gain, type 2 diabetes, high blood pressure and psychological issues, experienced significant, sustained weight loss while taking oral medication daily over a number of years to manage symptoms of the disease.
› Verified 3 days ago
Dr. Mohammad T Siddiqui, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1101 N Central Ave, Kissimmee, FL 34741 Phone: 407-851-5600 Fax: 407-438-0507 | |
Dr. Giovanni Hernandez, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1178 Cypress Glen Circle, Kissimmee, FL 34741 Phone: 407-943-8883 Fax: 407-943-8854 | |
Sidi A Elalaoui, MD Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 1952 N John Young Pkwy, Kissimmee, FL 34741 Phone: 407-343-1284 Fax: 407-343-1286 | |
Basher M Atiquzzaman, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 2400 N Orange Blossom Trail, Suite 302, Kissimmee, FL 34744 Phone: 407-932-6193 Fax: 407-932-6194 | |
Dr. Mukesh Kumar, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 601 Oak Commons Blvd, Kissimmee, FL 34741 Phone: 407-846-0626 Fax: 407-846-2371 | |
Dr. Adam L Griggs, D.O. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1121 N Central Ave, Suite B, Kissimmee, FL 34741 Phone: 407-933-1221 Fax: 407-933-0747 | |
Sajid Chaudhary, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 102 Park Place Blvd., Bldg D, Suite 2 &3, Kissimmee, FL 34741 Phone: 407-279-5069 Fax: 407-378-3076 |